India, Nov. 16 -- Instil Bio, Inc. (TIL) reported Monday a narrower third-quarter loss as research and development spending declined sharply.
Company Profile
Instil is a biotechnology company building a portfolio of asset-focused subsidiaries to develop therapies for unmet medical needs.
Third-Quarter 2026 Financial Results
For the quarter ended September 30, 2026, net loss narrowed to $4.23 million, or $0.62 per diluted share, from $13.59 million, or $2.01 per share, in the corresponding prior-year quarter.
R&D expenses fell to $0.23 million from $9.13 million. General and administrative costs declined to $5.83 million from $6.34 million.
Adjusted net loss narrowed to $3.33 million, or $0.48 per diluted share, from $11.82 million, or...